Israeli Innovations in Medical Technology
by Dr. Rachelle H.B. Fishman
(Updated February 2016)
There is virtually no area of medicine to which Israeli
devices have not made significant contributions - cardiology, genetics,
neurology and ophthalmology are but a few of the sciences
benefiting from advanced Israeli technology. Israeli scientists, universities
and companies are working to benefit the global health system - from
physician to patient to medical administrators and insurers.
Israeli medical and biotechnological innovations include
state-of-the-art surgical lasers, fully computerized no-radiation
diagnostic instrumentation for breast cancer, an intelligent medical sensor
that can be used to track and direct instruments to an exact
three-dimensional location in the heart or other organs via a real-time
virtual image, the fully flexible waveguide fiber for endoscopic surgery,
unique computerized monitoring systems for critical care patients,
pain-relieving transcutaneous devices, a revolutionary autoclave design to
combat AIDS and other infectious diseases and many more.
- No Inventions Without Investors
- Academic Research & Development
- Government's Technological Efforts
- Does it Work?
- Meeting Ethical Standards
- Focused Expansion
- Biting into the Future
- Smart Money
- Erecting a Managerial Structure
- Marketing Israel's Products
- "Heart Knows No Borders"
- Examples of Israeli Medical Innovations
No inventions without inventors
The most important resource in Israel is its human
capital, including the flood of Russian-speaking scientists, engineers and
programmers, who immigrated in the 1990s from the former Soviet Union. Many
of them excel in math, physics, material sciences and medical electronics.
In addition, over the years, close cooperation has
developed between medical research institutions and industry. This
cross-fertilization has bridged the once impenetrable gap between basic and
applied science and has made it easier for innovative technology to arrive
at your doctors office. Few today would argue against the rapidity of
advancements by medical manufacturers, based on the most updated research
and development that has taken place in the countrys universities and
Academic Research and Development
Each of Israels universities and research institutes
has established its own research authority. These authorities assist
professors in finding, applying for and administering grants and funding
for their research. Each has generated a commercial limb that also
initiates investor searches, helps private launches, assists commercial
exploitation of research by drafting and filing licensing agreements,
actively guides technology transfer and encourages patenting of new
discoveries before they are submitted to peer-reviewed journals, to prevent
the current worry – publish and perish.
Thus these research and development enterprises give the
universities a chance to profit from and reinvest the fruits of their
research by working through subsidiary companies while at the same time
increasing the potential for new development in industry. For instance,
medicine and medical equipment are the dominant start-up sectors at most
Israeli universities and at the same time provide the technological
expertise for most of these industries.
Ben Gurion University of the Negevs, Ben Gurion Negev
Technologies and Applications Ltd., for example, offers support in both
medicine and bioengineering. It has pioneered the Neuromedical Electrical
Stimulation Systems Ltd. (NESS), a glove-like device that can stimulate
movements in a paralyzed hand or arm. Another commercial innovation is the
Savyon Diagnostics rapid diagnostics kit for fungal infections.
Bar-Ilan Universitys Bar-Ilan Research and
Development Co. Ltd. spawned Medis El Cell Scan an advanced electro-optical
blood cell sorting device to diagnose and detect early stages of cancer.
Hadasit Medical Research Services and Development, an
enterprise of the Hadassah Medical Organization Ltd., in Jerusalem, has
facilitated innumerable licensing or joint ventures in cancer therapies,
osteoporosis, diabetes, cardiovascular disorders, orthopedics, diagnostics,
medical devices and laser technologies.
In 1966, The Technion – Israel Institute of
Technologys – Technion Research and Development Foundation, founded
Elbit Ltd., as a start-up company, considered the original progenitor of
the medical device industry in Israel. Today, it is a giant healthcare and
diagnostics conglomerate with sales of 970 million $US annually.
Tel-Aviv University – Ramot, with its Rad-Ramot
high-tech incubator in Tel Hashomer Hospital, has generated several
start-up companies. The now well-established Orgenics Diagnostics Ltd.,
produces ultra-high sensitive and fast diagnostic kits, and recently merged
with American giant, Selfcare Corp. Another younger success is Combact
which has a unique technology for rapid bacterial analysis.
Established in 1959, Yeda Research and Development Ltd.,
of The Weizmann Institute of Science, pioneered the concept of pure
research benefiting from its own applications. It has spawned thousands of
successful medical technology initiatives.
Yissum Research Development Company Ltd., of The Hebrew
University of Jerusalem was established in 1964. In 1997, it signed 130
contracts, half of them with companies abroad. One of its products is a
tiny, biodegradable chip developed by the Faculty of Dental Medicine, which
treats gum disease by slowly releasing chlorhexidine. It was acquired by
the local conglomerate Israel Chemicals and is now valued at 140 million
To avoid missing out on rapid developments across
disciplines, and to keep from becoming too competitive with each other, the
autonomous university research authorities formed an alliance, FURAD (Forum
of University Research Authority Directors), that pools and strengthens
their technological and administrative resources. FURAD helps to assure
that the Israeli academic community responds to rapidly-evolving changes in
the research funding environment, both in Israel and abroad, and stays in
touch with the networks of regional and global partnerships (with the
European Union, for example) and interdisciplinary research projects.
Jointly, the Research Authorities maintain and update a comprehensive
national database of Israeli academic research and development, lobby
government ministries for funding, expand global partnerships, and
contribute to and implement national scientific research policy.
The Governments Technological
The government is also actively involved in the medical
technological sector. Nearly half of the approximately 200 nascent
technologies under development in government supported incubators are
medical technologies, not to mention those in biotechnology and software.
Magnet, a program of the Chief Scientist of the Ministry
of Industry and Trade, has a five-year budget of over 200 million $US to
support carefully targeted generic technologies or pre-competitive
concepts, such as electro-optics or biomedical diagnostics, by coordinating
groups of academics and businesses.
Healthcare and medical technology especially electronics
has been identified as the most promising growth sector by the Healthcare
Department of the Israel Export Institute. Partner to making that possible
is the business and marketing effort of the 24 American-Israel Chambers of
Commerce, first created in 1953, and Associated in 1993, representing over
3,000 American business and professional members, based largely in
Minnesota and in the Chicago and Boston areas.
Does it Work?
Growth of medical technology depends not only on
insights and ideas, but on proof through rigorous testing for safety and
efficacy. Speed, not haste, is the motto when weighing public health needs
versus public health protection.
Testing of devices is controlled by the medical device
assessment department in the Ministry of Health, which over the years, has
adapted a process which corresponds with that of the U.S. Food and Drug
Administration (USFDA). This harmonization allows laboratory, animal and
clinical (those involving human beings) studies conducted in Israel to
qualify as proof for approval, as if they were conducted in the U.S. The
result is a streamlined approval process and a shortcut to marketing
Israeli medical technology in the U.S., making healthcare delivery more
efficient and up-to-date. The USFDA recently modified its procedures to
make the approval process more efficient by actively guiding inventors and
researchers in formulating their testing protocols to meet USFDA licensing
demands; thus, the focus was shifted from a test of the trials to a test of
the products themselves.
In contrast, Israeli government regulations require only
those medical devices which release radiation, contain components derived
from animal sources, or are coronary stents, to have ministry approval for
marketing in Israel. Expanded legislation to empower the Ministry of Health
to examine and/or approve all medical devices is currently being formulated
and is expected to be in effect by the turn of the century.
Meeting Ethical Standards
Israels system of ethical standards, established to
meet international criteria following the Helsinki agreements, is exacting.
Proposals to initiate clinical trials, for instance, must be reviewed by a
system of ethics committees, which convene in every hospital and medical
institute. Considerations are based on ethics, moral and religious
implications and social impact, as well as on health and safety grounds.
Examples of the complex questions the committees might ask could include:
Could a new contraceptive device be used to abort as well as prevent
pregnancy? or How would technology to determine brain death – which
often occurs before the heart stops beating – affect declaration of
‘the moment of death and thus, decisions about when organ donations
may be made?
Technological growth is geometric, not linear, with one
industrys previous inventions spawning new developments in another. This
trend comes into play, for example, with medical technologies which have
profited from previous developments in the electronic defense industries.
Opgal Medical Systems, a subsidiary of El-Op Electro-Optics Industries Ltd.
in Nes Ziona, specializes in thermal imaging, remote sensing, lasers, and
displays. Opgal Medicals IVA-2000 Thermal Imaging System for cardiac
surgery is based on thermal coronary angiography (TCA), a technology
originally developed for military uses like night vision and heat-seeking
surveillance. The improved accuracy in angiographic imaging, and in image
storage improves decision-making in the surgical operating theater and
benefits the entire health system, from physician (user), to patient
(consumer), to medical administrators and insurers, and back to the patient
(consumer). Medical insurance costs have been reduced because the number of
re-do operations is significantly reduced: the system documents the
procedure, reducing malpractice insurance; operating theaters are freed;
and the reduced recovery time from minimally invasive procedures cuts
bypass costs by half.
Once a device is created, its use during applications
invariably spins off other developments. A new thermal sensor, invented at
the Jerusalem College of Technology, for example, makes thermal imaging
readings more precise during an angiogram. The sensor will be incorporated
in the next generation of the OpGal line of products. Applications in
ocular surgery, neurosurgery, peripheral vascular surgery, cancer
detection, and dialysis control with this device are under discussion in
Europe, the U.S. and Israel.
Biting into the Future
Economic forecasts indicate a bright future for the
biotechnology and biomedical sectors in Israel. The medical technology and
devices sectors stand out with the highest growth of any sector during the
late 1990s. No fewer than 40% of the 1,500 start-up companies in Israel are
in the medical and life sciences arena, with no indication of a slowdown
well into the next millennium, according to a survey conducted by the
Science and Technology Forecasting Center at Tel Aviv University. By the
year 2003, forecasters say, Israeli biomedical and biotechnology industries
will have sales of 1.8 billion $US, almost six times the sales in 1997; and
investment in this sector will grow to 430 million $US in the year 2000,
and to 980 million $US in 2003. During this time, the number of expert
workers in the industry will increase to 3,400, a nearly three-fold
increase in six years.
According to Ernst & Young, investment analysts, the
very best prospects for the industrys growth, are in the medical
devices, bio-electronics, diagnostics and smart drugs sectors. Pure
biotechnology, on the other hand, requires greater investment and a longer
development time – more than twice the two-to-four-year average estimated
development time for medical devices.
The international accounting firm, Kesselman &
Kesselman PricewaterhouseCoopers showed in their Money Tree® Survey that
the average medical devices sector venture capital investment increased in
1998 by 42% to 2.2 million $US from 1.5 million $US in 1997, with most
medical device-based companies located in Haifa and northern Israel.
Despite the 4th quarter slowdown, 1998s 91 million $US in venture backed
investment was a massive 86% increase over the previous year, continuing a
trend started in the mid-1990s.
In spite of the need to overcome seemingly
insurmountable odds, such as distance, language, cultural differences, and
fluctuations in the continuing peace process, Israel has become a prime
site for international venture capital and technology-seeking funds,
especially since the beginning of the 1990s. Since 1992, more than 50
venture capital funds are investing in medical technologies, raising nearly
1.5 billion $US, about half of which was invested within six years. Medica
Investments of Medica Venture Partners, like the private Medmax, is a
unique fully-dedicated healthcare fund. Because of the high expertise and
longterm view, Medica takes a pro-active brokering interest in the business
and the science in all of the 11 biotech and medical device investments in
its 15 million $US portfolio. Interest in Israels medical technology by
giant multinationals like Bristol Myers-Squibb, General Electric, GEMS
(General Electric Medical Systems), Johnson & Johnson and Siemens has
grown increasingly competitive as Israels reputation for high-tech
innovation and ingenuity spreads. More industry is being developed locally,
for example ELGEMS, a joint venture formed in 1997 with Elscint, for the
design and manufacture of medical imaging products.
During 1995-97, Israels healthcare exports spiraled
upwards from 623 million $US to 990 million $US. The electro-medical
equipment sub-sector made the largest contribution to the industrys
growth during this time, accounting for a full 59% of total exports,
followed by pharmaceuticals and chemicals; biotechnology and diagnostics;
and medical supplies.
BIRDF, the U.S.-Israel Binational
Industrial Research and Development Foundation, matches Israeli
high-tech companies with strategic partners in the U.S. Instrumental in
establishing the commercially successful Israeli electronics,
communications, and software sectors, BIRDF recently prioritized new
biomedical technologies and the links among the biosciences and electronics
and computer sciences. And BIRDF is not alone. Recognizing this new and
emerging realm of endeavor, in April 1998, a joint seminar of BIRDF and
BSF, the U.S.-Israel Binational Science
Foundation, focused on three spheres that combine the expertise of cell
physiology, electronics and biomedicine: bio-chips and gene-chips;
bio-sensors and neuro-sensors; and nanotechnology.
Erecting a Managerial Structure
Whatever the means of development or method of
marketing, locally or internationally, with or without foreign partners,
medical devices need special expertise for patent protection before they
venture out of the laboratory. Israel has special skills in this area too,
boasting some 100 active patent attorneys. The primary protector firms are
Luzzatto & Luzzatto, Reinhold Cohn & Partners and Dr. Mark Friedman
Ltd., which, since arriving just five years ago, handles more than 50% of
all new high-tech patent applications actually written and filed in Israel.
The Achilles heel of the medical device, diagnostics and
biotechnology sectors is its youth and the commensurate lack of managerial
experience. But help is on the way.
The Israeli Biotechnology Organization, an industrial
arm working in cooperation with the Israel Manufacturers Association, is
trying to re-import managers, i.e., to convince Israeli executives
working in successful biomedical companies in the U.S. to participate in an
advisory and teaching capacity in Israel. A similar effort to fast-track
management is being made in the U.S. The U.S.-Israel Biotech Committee
(USIBC), a nonprofit Washington, D.C. organization, has set up a
Directors Program to encourage qualified Israeli administrators
and U.S. industry veteran directors to serve as board members for young
Israeli start-up companies, matching them according to need and expertise.
Another innovative means to infuse good management
skills is to interface young high-tech companies with an entirely new
industry in Israel: high-tech management companies, offering skills in
building management staff and creating management strategy in combination
with investments or strategic partnering. The addition of clinical research
organizations has facilitated the work to get medical developments through
the regulatory channels.
Marketing Israels Products
Management of Israeli medical technology means marketing
its products internationally. Being connected to the market, sensitive to
market needs, and also being able to persuade public opinion shapers to
adopt innovative technologies are challenges facing the new companies.
Partnering at the right moment is the key to success, but Israeli high-tech
companies have not done this as much as they could have.
Some medical technology firms tend to sell their
technologies to international investors at an early stage, rather than risk
going on to develop a larger company that would bring foreign currency into
the country. The concern is that if Israel becomes an R&D laboratory of
the mega-conglomerates of the world, the country, from a national
standpoint, is getting the minimum rather than the maximum value per
engineer – a pre-marketing company brings in 10 percent of the profits a
company with customers can obtain. Worse still, investors who buy companies
at the technology stage tend to identify the key people and persuade them
to leave Israel. But sometimes, the only way a smaller niche product in the
development stage will ever reach the market at all, is to sell out to a
bigger and more experienced company.
More and more companies are convinced of the value of
retaining R&D in Israel. Multi-billion dollar Siemens AG recently
singled Israel out, next to the U.S., as a target for high-tech cooperation
plans with future potential. More than 50 Israeli companies, including many
start-ups, produce many of the companys components.
Another multi-billion dollar mega-corporation, General
Electric Medical Systems (GEMS), has invested several hundred million
dollars in business ventures and acquisitions in Israel, setting up a local
umbrella company to focus on imaging, ELGEMS. GEMS has established two
global Centers of Excellence for advanced applications development of
Magnetic Resonance Imaging and for Nuclear Medicine products, hoping to
propel the company into the number one spot in radiation and imaging
Some of the other international companies currently
conducting business with Israel include Imagyn, Johnson & Johnson,
Pfizer, Purotec International, Univision Technologies and Uro-care
The Heart Knows No Borders
In the international arena, shared device testing can
aid peace efforts as well as medicine. The Heart Knows No Borders
project has effectively formed a network between Jordan, Israel and the
Palestinian Authority for testing two cardiac devices invented in Israel.
In 1996, two giant American medical device companies
with their Israeli developed products, Medtronic Vascular-Instent and
Scimed/Boston Scientific-Medinol, met with the U.S.-Israel Science &
Technology Commission, and the Devices Branch of the USFDA, to discuss
funding a proposal that would improve patient recruitment for
investigational device evaluation (IDE) clinical trials, and at the same
time, reap a peace bonus by joining professionals and patient populations
in the Middle East.
Submitted by the Duke Clinical Research Institute, the
proposal would combine patient recruitment into trials of the
Medtronic/InStent beStent-crimper combination and the Medinol/Boston
Scientific NIR 5-cell Primo stent for small vessel stenting. By making
patient characteristics sufficiently different conflict over competitive
recruitment of patients into each protocol is avoided and can actually help
shunt into each others trial inclusion groups.
Ten interventional cardiology sites in the region and in
the U.S. are participating in the studies, including the Rappaport Faculty
of Medicine, the Technion-Institute of Technology at the Rambam Medical
Center in Haifa, the Heart Institute at the Shaare Tzedek Hospital in
Jerusalem, the Queen Alia Heart Institute-King Hussein Medical Center and
the University of Jordan.
Equally important, a pilot test of the potential of
transmitting digitized angiographic images in parallel with standard cine
film image analyses is being assessed for speed and accuracy at the
Washington Heart Center, a leading U.S. laboratory. If paperless data
analysis can be proven, this sub-study would revolutionize angiography,
another aspect not lost on the USFDA. Devices and medical products are
becoming global, moving in international commerce between countries, a
challenge that USFDA has been addressing more than in previous years.
Paperless case reporting would significantly improve international
harmonization and standards while saving resources.
By encouraging neighboring nations to work together,
the Heart Knows No Borders project facilitates the solution of shared
common problems, collective public health priorities that can best be
addressed by cooperative efforts...[and is] a healthy way to normalize
relations, said Shimon Peres, former Prime Minister of Israel, founder
of the Peres Institute for Peace, who was instrumental in bringing the
project to fruition.
In other areas of biomedical research, the U.S. National
Institute of Health (NIH) has granted funds for projects in Israel ranging
from angiographic research to X-ray crystallography. Sometimes, new
procedures can be developed more quickly in Israel to the benefit of all
Examples of Medical Devices & Equipment Pioneered in Israel
* Weizmann University Professor Zelig Eshhar
pioneered the innovative adaptive immunotherapy technique to treat cancer in Israel, which is now being hailed as a "potentially extraordinary development" in cancer treatment. In an article published in Science Translational Medicine, University of Pennsylvania’s Abramson Cancer Center and the Perelman School of Medicine reported that 27 out of 29 patients suffering from advanced blood cancer saw their disease go into remission or disappear completely when treated with adaptive immunotherapy. The treatment involves the patient receiving genetically modified T-cells equiped with chimeric antigen receptors, which are then able to target and destroy the metastasizing tumor cells.
* ESC Medical Systems Ltd. –
electro-optic medical devices applying proprietary pulsed light technology,
for non-invasive treatment of skin cancer, benign lesions, as well as for
treatment of varicose veins, skin rejuvenation and hair removal.
* SOL-GEL Technologies Ltd. – glass microcapsules
containing UV absorbers increase sunblocking by allowing admixture of
otherwise incompatible ingredients to maximize photostability and efficacy,
and form a layer on but without chemicals contacting the skin.
* Tuttnauer Co. Ltd. in Jerusalem –
is a world leader in steam and gas autoclaves of all sizes for sterilizing
medical instruments for clinics, hospitals and laboratories.
Cardiac stents are implanted in blood
vessels during angioplasty to keep occluded vessels from re-closing:
* InStent with American partner, Medtronic/beStent line
and the crimper.
* Medinol with American partner, Boston Scientific/Nir
cardiac stent line market leader.
* Angiosonics Inc. – a catheter-delivered ultrasound
for thrombolysis, a non-invasive therapeutic ultrasound in the heart; early
studies have shown that it could break up clots in peripheral vessels.
* Laser Industries – a Sharplan holmium/yag laser for
unblocking multiply-occluded coronary vessels.
||* Perio – biodegradable chip with slow
release chlorhexidine to treat gum disease – from the Hadassah Faculty of
Dental Medicine, sold to Israel Chemicals.
* CAPTEK – gold, platinum, palladium metal composite for aesthetic,
high strength dental crowns and bridges that reduce plaque by 10% on
||* BioSense Ltd., CARTA & NOGA
systems – hardware-software non-fluoroscopic intrabody navigation and 3-D
mapping system, hailed as the missing, real-time link between diagnostics
||* ASI – APPLIED SPECTRAL IMAGING –
Cytogenetics and pathology have been revolutionized by SKYTM (Spectral karyotyping), SkyVision, and the
SpectraCube™ to sort chromosomes, cells or tissues in colors reflecting
|* Trans-Scan – T-Scan devices which
significantly improve mammography diagnostic accuracy with no additional
* SophisView Technology Ltd. (SVT) – MACOM 4000 and MAPP 4000
digitized mammography which enhance sub-millimeter details.
||* Medis-El – Nuritor, an advanced,
compact and portable analog/digital EEG
* Mindsense Ltd – kits for detecting mental illnesses.
* Imexco General Ltd. – Neuritor, a computerized neurological
brain-monitor for the acquisition & analyses of multichannel EEG/ECG
signals in real time.
* Riemed Ltd. – Intra-View, a new generation of transcranial Doppler
including intracranial, extracranial, peripheral vascular and
intraoperative simultaneous investigation of two cerebral sites.
|* MedEye Medical Imaging Ltd. –
AngioVision for retinal diagnosis, digital angiographic acquisition and
* Talia Technology – Retina Thickness Analyzer (RTA), a combined
electro-optical laser and conventional optical instrument for the
non-invasive measurement of ocular pathologies. Its Laser Slit has been
marketed since 1996.
* Shapiro Instruments (Israel), Subsidiary of Shapiro-Evans Perceptions
Ltd. (UK) – Innovative optometric examinations using simple technology,
but sophisticated philosophy.
||* Delve Medical Ltd. – an electronic
stethoscope with phonocardiograph instrumentation to receive and digitally
process body sounds, filter out interfering noises, and graphically present
the sounds on a display screen.
|* Diagnostic Sleep Laboratory Ltd. –
diagnostic equipment for sleep recordings (respiration, ECG, movements).
||* First Care (Jerusalem) – bandage
that enables self-application to wounds; can also block arterial flow and
increase distal hemostatic pressure.
* Mennen Medical Ltd. – Cathlab patient monitoring equipment for
* Wais Med – Bone Injection Gun (B.I.G.™), treats emergency
patients with drugs and other fluids by intraosseous infusion, directly
into the bone marrow.
||* CBF Medical – Ciliary Beat Frequency
monitor attaches to a standard endoscope, to optically measure the
frequency waves of ciliary cells as new diagnostic for mucociliary function
in respiratory disease and tubal infertility.
||* Myriad Ultrasound Systems –
SoundScan Compact and SoundScan 2000 bone quantitative sonometers which
detect subtle changes in bone quality, as in osteoporosis and other bone
* Sunlight Ultrasonics Omnisense – the only sonometer providing
multiple sites skeletal bone density assessment.
||* LMS or CHAI (life in Hebrew) –
the USFDA-approved Sure-Closure Skin-Stretching system, replacing costly
skin grafts or flaps to close large wounds and avoid disfiguring scars;
newer applications focus on polymer technology, a medium for graft storage
and a first-ever wound gel for dermal ulcers and chronic wounds.
* SPM RECOVERY – sealed chamber to apply ozone/oxygen mixture and
bacterial medium to infectious wounds, post-surgical wounds, trophic
ulcers, decubitus, and burns.
||* SIL-K – silicone sheeting from
Kibbutz Degania, which has USFDA approval, eases intense pain after
scar-tissue removal operations.
||* Oridion (originally Spegas) –
pioneered infra-red measurement of carbon dioxide exhaled by patients at
all points of care. u Elrad Analytical Systems – systems which monitor
gases in patients during medical treatment.
||* Optomedic Medical Technologies – the
Kaplan PenduLaser, a carbon dioxide surgical laser system.
* Hadassah-based Nanomed with US-based Summit – a unique movable arm
delivery system for cold action excimer laser for intra-ocular surgery.
* Nanonics Lithography – the breakthrough Near Field Optics, which can
focus laser beams at a tenth of a micron.
* A number of companies have developed a broad range of innovative
optical glass rods as active media for solid state medical lasers and high
intensity luminescence (replacing gas and dye media).
|* NurtureLife the Patir incubator in
Jerusalem – a device for checking the amount of milk an infant drinks
* Hisense Ltd. – 200 $US monitor called Babysense, sends out an alarm
if a baby stops breathing while asleep, as happens in SIDS (sudden infant
* SPO Medical Equipment Ltd. – Long Life, an early warning monitor,
which senses lowered breathing and pulse levels and could prevent SIDS.
||* Medco Electronic Systems Ltd. –
Femo, a non-invasive fetal ECG and fetal heart rate monitoring system with
true beat to beat variability, which prevents unnecessary C-section
* Cybro Medical – an optical and non-invasive fetal monitor based on
pulse oximetry complementary to the ECG to reduce unnecessary C-section
|* Vital Medical – the Tissue Vitality
Analyzer (TVA), expected to save lives and millions of dollars by detecting
failed organs before implantation.
||* Titan Electronics – a compact,
pocket-sized, battery-powered Transcutanous Electronic Nerve Stimulation
(TENS) stimulator to relieve menstrual pain.
|Radiology & Medical
||* InSight Therapeutics and GEMS – new
joint venture TxSonics produce state-of-the-art devices for image guided
* UltraGuide 1000 – new add-on device for ultrasound-assisted
* Real-time Radiography Readout (R3) Ltd. – a joint venture of YISSUM
(the Research Development Company of The Hebrew University of Jerusalem)
and T.T.I. (Target Technologies Israel) Ltd.
* X-Medica – new concepts in filmless digital X-ray, for the next
generation of medical imaging.
||* Haifa-based Pluristem Theraputics developed an anti-radiation therapy, able to cure almost all patients exposed to “nonconventional radiological incidents,” such as dirty bombs or attacks on nuclear power plants. The therapy is placenta-based, and involves injecting patients who have been exposed to lethal doses of radiation with a serum. The United States began testing this new treatment in early 2016 on large animals, as part of a Homeland Security program to protect people in case of a radioactive attack or catastrophie.
|* NESS (miracle in Hebrew) – a
USFDA-approved glove-like device that aids therapy in restoring function to
paralyzed hands and arms.
Portable Medical Technology
||* Card Guard with a Hewlett-Packard UK
alliance – provides software-hardware systems for Cardiology/Portable
ECG, Pulmonology/SpiroPhone Transtelephonic Spirometer, and Ob/Gyn/Portable
Fetal-Maternal Monitoring Device.
* Imexco General produces CardioScope – a pocket cardiological
diagnostic ECG monitor, with storage, printer, and transmission
* TzamalCare – innovative remote controlled systems, Infu-Tech and
Infu-Net diffused infrared wireless transmitters and readers to monitor and
control infusion therapy from a remote station.
|* MTRE Advanced Technology – ALLON
2000 returns and maintains normothermia of core body temperature into
trauma management, during surgery and post-op.
* Medisim – Up-Grade gives quick, accurate, digital readout of body
||* Influence – a device to treat
* Medispec Ltd. and Direx – devices for treating kidney stones,
gallstones and various prostate disorders.
* Opgal Medical Systems, a division
of Opgal Optronics Industries Ltd. in Karmiel – the IVA-2000 Thermal
Imaging System for real-time thermal images of blood flow through exposed
coronary arteries, without ingesting toxic contrast materials or exposure
* OrSense Ltd., a start-up – Hemosense, an
infrared-based bloodless blood test of hemoglobin and hematocrit.
* Vascular Technologies Ltd. – award-winning device
attaches to a standard catheter to indicate correct insertion of an
infusion needle into a vein.